Jazz Pharmaceuticals (JAZZ) investor relations material

Executive summary

• Annual General Meeting scheduled for July 23, 2026, in Dublin, Ireland, with voting available online, by mail, or in person.

• Shareholders as of May 28, 2026, are eligible to vote on key proposals, including director elections and auditor appointment.

Voting matters and shareholder proposals

• Election of three directors to serve until the 2029 Annual General Meeting: Bruce C. Cozadd, Heather Ann McSharry, and Rick E Winningham.

• Advisory vote to approve KPMG as independent auditors for fiscal year ending December 31, 2026, and authorize the Board to set their remuneration.

• Advisory vote on executive compensation as disclosed in the proxy statement.

• Proposal to grant the Board authority to allot and issue ordinary shares under Irish law.

• Proposal to allow the Board to issue shares for cash without pre-emption rights.

• Proposal to approve adjournment of the meeting if more time is needed to solicit proxies for share issuance proposals.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and share issuance authorities.